Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05749900
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-03-01
First Post:
2023-02-19
Brief Title:
First-line Trastuzumab Gemcitabine Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer a Multicenter Open-label Single-arm Phase IbII Trial HERBOT
Sponsor:
Yonsei University
Organization:
Yonsei University
Organization Data
Organization:
Yonsei University
Class:
OTHER
Study ID:
4-2022-1610
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Yonsei University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None